

Test Report**Report No.: GZAFF1812022031S001****Date: Jan 14 2019**

Client name: Fulmina Hong Kong
Client address: 19/F, Kai Tak Commercial Bldg., 161 Connaught Road, Central, Hong Kong SAR
Sample name: Lapis Pro
Sample Batch No.: /
Product Date: 2018-10-13
Manufacturer: /
Sample other information: LOT NO.: 0012017

Above sample(s) was/were submitted and certified by the client, SGS quoted the information with no responsibility as to the accuracy, adequacy and/or completeness.

SGS Sample No.: GZAFF1812022031S.001
SGS reference No.: UF/2018/C0400A-01, SHE18-11666/1, SHAFD1827667101, CANAF1825579901
Date of sample received: Dec. 10, 2018
Testing period: Dec. 10, 2018 ~ Jan. 11, 2019

TEST(S) REQUESTED:

Selected test(s) as requested by the applicant

TEST METHOD(S):

Please refer to next page(s)

TEST RESULT(S):

Please refer to next page(s)

SAMPLE DESCRIPTION: Sample in bottle

This test report has been drafted in English and maybe translated into other languages, The English version shall prevail.

SGS-CSTC Standards Technical Services Co., Ltd. Guangzhou Branch

SGS Authorized Signature
胡楷崎 Catherine Hu

Unless otherwise agreed in writing, this document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

GZAF 173399

Test Report

Report No.: GZAFF1812022031S001

Date: Jan 14 2019

This test report refers only to items tested. This document cannot be used for publicity, without prior written approval of the SGS.

TEST RESULT(S):

A:

Test Item	Unit	Test Method (Reference to)	Test Result
Aerobic plate count	CFU/g	GB 4789.2-2016	< 10
Coliforms	MPN/g	GB 4789.3-2016, the first method	< 0.3
Moulds & Yeasts	CFU/g	GB 4789.15-2016, the first method	< 10
Salmonella	/25g	GB 4789.4-2016	Not Detected
Staphylococcus Aureus	/25g	GB 4789.10-2016, the first method	Not Detected

B:

Test Item	Unit	Test Method (Reference to)	Test Result	Limit of Quantitation
Color	/	GB 16740-2014	Content and capsule shell have the proper color of product	/
Taste & Odor	/		With proper taste and odor of the products, no abnormal odor	/
State	/		Content have the proper state of products, no visible external impurities	/

C^①:

Test Item	Unit	Test Method (Reference to)	Test Result	Limit of Quantitation
Acid value	mg/g	GB 5009.229-2016, the first method	1.7	/
Peroxide value	g/100g	GB 5009.227-2016, the first method	0.091	/
Total flavone (as rutin)	mg/100g	Technical standards for Testing & Assessment of Health Food, Sanitation department of the People's Republic of China, February 2003, Part 2, 24	1.3×10 ²	/
6# Solvent residue	mg/kg	GB 5009.262-2016, HS-GC-FID	ND	10.0
α-Tocopherol	mg/kg	GB/T 26635-2011, HPLC-DAD	663	25
β-Tocopherol	mg/kg		ND	25
γ-Tocopherol	mg/kg		297	25
δ-Tocopherol	mg/kg		ND	25
Tocopherol (α+β+γ+δ)	mg/kg		960	/
PG	mg/kg	SN/T 1050-2014, HPLC-DAD	ND	2
TBHQ	mg/kg		ND	2

Page 2 of 21

RAND: 37374015



Unless otherwise agreed in writing, this document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

GZAF 173400

SGS-CSI Standards Technical Services Co., Ltd.
Guangzhou Branch Testing Center for Food and Food Laboratory

No.196 Kazhu Road, Sciencetech Park, Guangzhou Economic & Technology Development District, Guangzhou, China 510663 t 400-691-0488 f (86-20) 82075027 www.sgs.com.cn
中国·广州·经济技术开发区科学城科珠路198号 邮编: 510663 t 400-691-0488 f (86-20) 82075027 e sgs.china@sgs.com

Test Report

Report No.: GZAFF1812022031S001

Date: Jan 14 2019

Test Item	Unit	Test Method (Reference to)	Test Result	Limit of Quantitation
BHA	mg/kg		ND	2
BHT	mg/kg		4	2
Aflatoxin B ₁	µg/kg	GB 5009.22-2016, the third method, HPLC-FLD	ND	0.3
Benzo(a)pyrene	µg/kg	GB 5009.27-2016, HPLC-FLD	1.0	0.5

D①:

Test Item	Unit	Test Method (Reference to)	Test Result	Limit of Quantitation
Dibutyl Phthalate (DBP)	mg/kg	GB 5009.271-2016, the second method, GC-MS	6.4	0.3
Diisobutyl Phthalate (DIBP)	mg/kg		ND	0.5
Bis-(2-ethylhexyl) phthalate (DEHP)	mg/kg		17.2	0.5
Diallyl Phthalate (DAP)	mg/kg		ND	0.5
Benzyl butyl Phthalate (BBP)	mg/kg		ND	0.5
Di-n-octyl Phthalate (DNOP)	mg/kg		ND	0.5
Dihexyl phthalate (DnHP/DHXP)	mg/kg		ND	0.5
Dimethyl Phthalate (DMP)	mg/kg		ND	0.5
Diethyl Phthalate (DEP)	mg/kg		ND	0.5
Dipentyl Phthalate (DPP)	mg/kg		ND	0.5
Dicyclohexyl Phthalate (DCHP)	mg/kg		ND	0.5
Di-n-nonyl Phthalates (DNP)	mg/kg		ND	0.5
Diphenyl Phthalate (DPhP)	mg/kg		ND	0.5
Bis(2-methoxyethyl) phthalate (DMEP)	mg/kg		ND	0.5
Bis(4-methyl-2-pentyl) Phthalate (BMPP)	mg/kg		ND	0.5
Bis(2-ethoxyethyl) Phthalate (DEEP)	mg/kg		ND	0.5
Bis(2-n-butoxyethyl) Phthalate (DBEP)	mg/kg		ND	0.5
Diisononyl ortho-phthalate (DINP)	mg/kg		ND	9.0

E①:

Test Item②	Unit	Test Method (Reference to)	Test Result	Limit of Quantitation
C18:2t trans linolelaidic	%(A/A)	GB 5009.168-2016,	0.6	0.1



Unless otherwise agreed in writing, this document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

GZAF 1734015

Test Report

Report No.: GZAFF1812022031S001

Date: Jan 14 2019

Test Item®	Unit	Test Method (Reference to)	Test Result	Limit of Quantitation
C18:1t trans-elaidic	%(A/A)	the third method, GC-FID	0.2	0.1
C22:6-4c,7c,10c,13c,16c,19c cis-4,7,10,13,16,19-docosahexaenoic (DHA)	%(A/A)		ND	0.1
C22:2-13c,16c cis-13,16-docosadienoic	%(A/A)		ND	0.1
C20:5-5c,8c,11c,14c,17c cis-5,8,11,14,17-eicosapentaenoic(EPA)	%(A/A)		ND	0.1
C20:3-11c,14c,17c cis-11,14,17-eicosatrienoic	%(A/A)		ND	0.1
C20:4-5c,8c,11c,14c cis-5,8,11,14-eicosatetraenoic/arachidonic	%(A/A)		ND	0.1
C20:3-8c,11c,14c cis-8,11,14-eicosatrienoic	%(A/A)		ND	0.1
C20:2-11c,14c cis-11,14-eicosadienoic	%(A/A)		ND	0.1
C18:3 (ALA)-9c,12c,15c cis-9,12,15-octadecatrienoic/linolenic	%(A/A)		0.4	0.1
C18:3 (GLA)-6c,9c,12c cis-6,9,12-octadecatrienoic/r-linolenic	%(A/A)		ND	0.1
C18:2 -9c,12c cis-9,12-octadecadienoic/ linoleic	%(A/A)	GB 5009.168-2016, the third method, GC-FID	45.0	0.1
C24:1-15c cis-15-tetracosenoic/nervonic	%(A/A)		ND	0.1
C22:1-13c cis-13-docosenoic/erucic	%(A/A)		0.2	0.1
C20:1-11c cis-11-eicosenoic	%(A/A)		0.2	0.1
C17:1-10c 10-heptadecenoic	%(A/A)		ND	0.1
C18:1-9c cis-9-octadecenoic/oleic	%(A/A)		37.7	0.1
C16:1-9c cis-9-hexadecenoic/palmitoleic	%(A/A)		0.1	0.1
C15:1-10c 10-pentadecenoic	%(A/A)		ND	0.1
C14:1-9c cis-9-tetradecenoic/myristoleic	%(A/A)		ND	0.1
C24:0 lignoceric	%(A/A)		0.2	0.1
C23:0 tricosanoic	%(A/A)		ND	0.1
C22:0 docosanoic/behenic	%(A/A)		0.1	0.1
C21:0 heneicosanoic	%(A/A)		ND	0.1
C20:0 eicosanoic/arachidic	%(A/A)		0.6	0.1
C18:0 octadecanoic/stearic	%(A/A)		5.4	0.1
C17:0 heptadecanoic/margaric	%(A/A)		ND	0.1

Page 4 of 21

RAND: 37374015



Unless otherwise agreed in writing, this document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

GZAF 173402

No.198 Keshu Road, Sciencetech Park, Guangzhou Economic & Technology Development District, Guangzhou, China 510663 t 400-691-0488 f (86-20) 82075027 www.sgs.com.cn
中国·广州·经济技术开发区科学城科珠路198号 邮编: 510663 t 400-691-0488 f (86-20) 82075027 e sgs.china@sgs.com

Member of the SGS Group (SGS SA)

Test Report

Report No.: GZAFF1812022031S001

Date: Jan 14 2019

Test Item®	Unit	Test Method (Reference to)	Test Result	Limit of Quantitation
C16:0 hexadecanoic/palmitic	%(A/A)		9.1	0.1
C15:0 pentadecanoic	%(A/A)		ND	0.1
C14:0 tetradecanoic/myristic	%(A/A)		ND	0.1
C13:0 tridecanoic/tridecanoic	%(A/A)		ND	0.1
C12:0 dodecanoic/lauric	%(A/A)	GB 5009.168-2016, the third method, GC-FID	ND	0.1
C11:0 Undecanoic	%(A/A)		ND	0.1
C10:0 decanoic/capric	%(A/A)		ND	0.1
C8:0 octanoic/caprylic	%(A/A)		ND	0.1
C6:0 hexanoic/caproic	%(A/A)		ND	0.1
C4:0 butanoic/butyric	%(A/A)		ND	0.1

F:

Test Item	Unit	Test Method (Reference to)	Test Result	Limit of Quantitation
Mercury (Hg)	mg/kg	GB 5009.17-2014, Section 1, the first method, AFS	ND	0.010
Total Arsenic (As)	mg/kg	GB 5009.11-2014, Section 1, the first method, ICP-MS	ND	0.010
Lead (Pb)	mg/kg	GB 5009.12-2017, the second method, ICP-MS	ND	0.05
Fructose	g/100g	GB 5009.8-2016, the first method, HPLC-RID	ND	0.20
Glucose	g/100g		ND	0.20
Sucrose	g/100g		ND	0.20
Lactose	g/100g		ND	0.20
Maltose	g/100g		ND	0.20

G①③:

Test Item	Unit	Test Method (Reference to)	Test Result	Limit of Quantitation
Cholesterol	mg/kg	GB/T 25223-2010, GC-FID	ND*	100
Cholestanol	mg/kg		ND*	100
Brassicasterol	mg/kg		ND*	100
Campesterol	mg/kg		1063*	100
Stigmasterol	mg/kg		994*	100

Page 5 of 21

RAND: 37374015



Unless otherwise agreed in writing, this document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

GZAF 173403

SGS-CSI Standards Technical Services Co., Ltd.
Guangzhou Branch Testing Center for Food Laboratory

No.196 Kazhu Road, Sciencetech Park, Guangzhou Economic & Technology Development District, Guangzhou, China 510663 t 400 - 691 - 0488 f (86-20) 82075027 www.sgs.com.cn
中国·广州·经济技术开发区科学城科珠路198号 邮编: 510663 t 400 - 691 - 0488 f (86-20) 82075027 e sgs.china@sgs.com

Member of the SGS Group (SGS SA)

Test Report

Report No.: GZAFF1812022031S001

Date: Jan 14 2019

Sitosterol	mg/kg	4135*	100
Erythrodil	mg/kg	ND*	100
Uvaol	mg/kg	ND*	100

H: Pesticide residue^{①③}

Test Method: In house method, analysis was performed by GC-MS, LC-MSMS.
(Substances in the List of Pesticides Residue)

Code	Substance Name	Test Result mg/kg	Limit of Quantitation mg/kg
7	Bifenthrin	0.01	0.01
17	Dimethipin	NR	0.05
55	Propargite	0.08	0.01
58	tau-Fluvalinate	0.10	0.05
-	Other tested Pesticides Residue in list	ND	-

Appendix:

Full list of tested Pesticides Residue:

Code	Test Item	Limit of Quantitation (mg/kg)
1	Aldicarb (Sum of Aldicarb, DeAldicarb-sulfone and Aldicarb sulfoxide)	/
2	Aldicarb	0.01
3	Aldoxycarb/Aldicarb sulfone	0.01
4	Aldicarb sulfoxide	0.01
5	Amitraz	0.01
6	Benfuracarb	0.01
7	Bifenthrin	0.01
8	Chlordane (Sum of cis-Chlordane and trans-Chlordane)	/
9	cis-Chlordane	0.01
10	Trans-Chlordane	0.01
11	Chlormequat chloride	0.02
12	Chlorpyrifos	0.01
13	Clethodim	0.01
14	Cyhalothrin & λ-Cyhalothrin	0.02
15	Cypermethrin & Beta-Cypermethrin	0.02
16	Dicofol	0.01
17	Dimethipin	0.05
18	Dimethoate	0.01
19	Diquat	0.01



Unless otherwise agreed in writing, this document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

GZAF 173404

Test Report

Report No.: GZAFF1812022031S001

Date: Jan 14 2019

Code	Test Item	Limit of Quantitation (mg/kg)
20	Endosulfan (Sum of α -endosulfan, β -endosulfan, endosulfan sulfate)	/
21	α -Endosulfan	0.01
22	β -Endosulfan	0.01
23	Endosulfan sulfate	0.01
24	Ethion	0.01
25	Fenamiphos	0.01
26	Fenpropathrin	0.01
27	Fenthion (sum of Fenthion, Fenthion-sulfone and Fenthion-sulfoxide)	/
28	Fenthion	0.01
29	Fenthion-sulfone	0.01
30	Fenthion-sulfoxide	0.01
31	Fenvalerate & Esfenvalerate	0.02
32	Flucythrinate	0.01
33	Flusilazole	0.01
34	Glyphosate	0.05
35	Haloxypop-methyl & Haloxypop-P-methyl	0.01
36	Heptachlor (Sum of Heptachlor and Heptachlor epoxide)	/
37	Heptachlor epoxide (Isomer B)	0.01
38	Heptachlor	0.01
39	kresoxim-methyl	0.01
40	Monocrotophos	0.01
41	Paclobutrazol	0.01
42	Paraquat	0.01
43	Parathion	0.01
44	Parathion-methyl	0.01
45	Permethrin	0.01
46	Phorate (Sum of Phorate, Phorate sulphone and Phorate sulfoxide)	/
47	Phorate	0.01
48	Phorate sulphone	0.01
49	Phorate sulfoxide	0.01
50	Phosalone	0.01
51	Piperonyl butoxide	0.01
52	Prochloraz & Prochloraz-manganese chloride complex	0.01
53	Procymidone	0.01
54	Profenophos	0.01



Unless otherwise agreed in writing, this document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

GZAF 173405

Test Report

Report No.: GZAFF1812022031S001

Date: Jan 14 2019

Code	Test Item	Limit of Quantitation (mg/kg)
55	Propargite	0.01
56	Pyriproxyfen	0.01
57	Quintozene	0.01
58	tau-Fluvalinate	0.05
59	Thiodicarb	0.01
60	Trifluralin	0.01

I: Qualitative analysis of 360 Chemicals for clinical use®

Test Method: With reference to Method of Test for Adulterants in Chinese Medicine and Foods.

Analysis was performed by TLC, LC/MS/MS, or GC/MS.

(Substances in the List of 360 Chemicals for clinical use)

Substance Name	Unit	Kind	Test Result	Limit of Detection
All tested Chemicals for clinical use in appendix	mg/kg	-	Not Detected	-

Appendix:

Full list of tested 360 Chemicals for clinical use

Test Items	Unit	Kind	Limit of Detection
Vardenafil analogue (Molecular weight: 312.37)	mg/kg	Agents used in the urinary system	1800
7-Keto dehydroepiandrosterone	mg/kg	Agents used in the urinary system	3000
Acetil acid	mg/kg	Agents used in the urinary system	1500
Acetilildenafil	mg/kg	Agents used in the urinary system	600
Aminotadalafil	mg/kg	Agents used in the urinary system	900
Carbodenafil	mg/kg	Agents used in the urinary system	1500
Chloropretadalafil	mg/kg	Agents used in the urinary system	1500
N-Desmethylsildenafil	mg/kg	Agents used in the urinary system	3000
N-Desmethylacetildenafil	mg/kg	Agents used in the urinary system	3000
Dimethylsildenafil	mg/kg	Agents used in the urinary system	3000
Gendenafil	mg/kg	Agents used in the urinary system	3000
Homosildenafil	mg/kg	Agents used in the urinary system	1350
Hydroxyacetildenafil	mg/kg	Agents used in the urinary system	600
Hydroxyhomosildenafil	mg/kg	Agents used in the urinary system	1200
Hydroxythiohomosildenafil	mg/kg	Agents used in the urinary system	1650
Hydroxyvardenafil	mg/kg	Agents used in the urinary system	1500
Imidazosagatriazinone	mg/kg	Agents used in the urinary system	1200
N-Desethylvardenafil	mg/kg	Agents used in the urinary system	3000
Norneosildenafil	mg/kg	Agents used in the urinary system	1000

Page 8 of 21

RAND: 37374015



Unless otherwise agreed in writing, this document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

GZAF 173406

SGS-CSI Standards Technical Services Co., Ltd.
Guangzhou Branch

No.198 Kazhu Road, Science Park, Guangzhou Economic & Technology Development District, Guangzhou, China 510663 t 400-691-0488 f (86-20) 82075027 www.sgs.com.cn
中国·广州·经济技术开发区科学城科珠路198号 邮编: 510663 t 400-691-0488 f (86-20) 82075027 e sgs.china@sgs.com

Member of the SGS Group (SGS SA)

Test Items	Unit	Kind	Limit of Detection
Piperiacetildenafil	mg/kg	Agents used in the urinary system	3000
Piperidenafil	mg/kg	Agents used in the urinary system	1500
Sildenafil	mg/kg	Agents used in the urinary system	1200
Tadalafil	mg/kg	Agents used in the urinary system	600
Thiodimethylsildenafil	mg/kg	Agents used in the urinary system	450
Thiohomosildenafil	mg/kg	Agents used in the urinary system	450
Thiosildenafil	mg/kg	Agents used in the urinary system	450
Vardenafil	mg/kg	Agents used in the urinary system	1800
Noracetildenafil	mg/kg	Agents used in the urinary system	300
Acetylvaridenafil	mg/kg	Agents used in the urinary system	600
Nortadalafil	mg/kg	Agents used in the urinary system	1500
Dithio-desmethyl-carbodenafil	mg/kg	Agents used in the urinary system	1500
Fenfluramine	mg/kg	Weight loss Drug	30
Mephentermine	mg/kg	Weight loss Drug	60
N-Desmethyisibutramine	mg/kg	Weight loss Drug	3000
N-Didesmethyisibutramine	mg/kg	Weight loss Drug	3000
Orlistat	mg/kg	Weight loss Drug	30
Rimonabant	mg/kg	Weight loss Drug	3000
Sibutramine	mg/kg	Weight loss Drug	1200
Synephrine	mg/kg	Weight loss Drug	450
Cetilistat	mg/kg	Weight loss Drug	1500
Lorcaserin	mg/kg	Weight loss Drug	60
2,4-Dinitrophenol	mg/kg	Weight loss Drug	3600
Acetaminophen	mg/kg	Antipyretics and Analgesics	300
Allopurinol	mg/kg	Antipyretics and Analgesics	600
Aminopyrine	mg/kg	Antipyretics and Analgesics	900
Aspirin	mg/kg	Antipyretics and Analgesics	600
Benzbromarone	mg/kg	Antipyretics and Analgesics	900
Bucetin	mg/kg	Antipyretics and Analgesics	600
Colchicine	mg/kg	Antipyretics and Analgesics	750
Ethoxybenzamide	mg/kg	Antipyretics and Analgesics	600
Flurbiprofen	mg/kg	Antipyretics and Analgesics	150
Ibuprofen	mg/kg	Antipyretics and Analgesics	1200
Indomethacin	mg/kg	Antipyretics and Analgesics	1200
Ketoprofen	mg/kg	Antipyretics and Analgesics	450
Mefenamic acid	mg/kg	Antipyretics and Analgesics	900



Unless otherwise agreed in writing, this document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

GZAF 173407

Test Items	Unit	Kind	Limit of Detection
Naproxen	mg/kg	Antipyretics and Analgesics	900
Oxyphenbutazone	mg/kg	Antipyretics and Analgesics	450
Phenylbutazone	mg/kg	Antipyretics and Analgesics	750
Piroxicam	mg/kg	Antipyretics and Analgesics	600
Probenecid	mg/kg	Antipyretics and Analgesics	900
Salicylamide	mg/kg	Antipyretics and Analgesics	600
Sulindac	mg/kg	Antipyretics and Analgesics	750
Acetophenetidin	mg/kg	Antipyretics and Analgesics	3600
Benzydamine	mg/kg	Antipyretics and Analgesics	348
Bufexamac	mg/kg	Antipyretics and Analgesics	1650
Fenbufen	mg/kg	Antipyretics and Analgesics	1875
Flufenamic acid	mg/kg	Antipyretics and Analgesics	4050
Etodolac	mg/kg	Antipyretics and Analgesics	600
Dipyrone	mg/kg	Antipyretics and Analgesics	600
Propyphenazone	mg/kg	Antipyretics and Analgesics	3000
Celecoxib	mg/kg	Antipyretics and Analgesics	3000
Noraminopyrine	mg/kg	Antipyretics and Analgesics	2400
Bromhexine	mg/kg	Antitussives&Expectorants	1200
Carbetapentane	mg/kg	Antitussives&Expectorants	30
Dextromethorphan	mg/kg	Antitussives&Expectorants	1500
Guaifenesin	mg/kg	Antitussives&Expectorants	2400
Phenacetin	mg/kg	Antitussives&Expectorants	300
Ambroxol	mg/kg	Antitussives&Expectorants	600
Cloperastine	mg/kg	Antitussives&Expectorants	1500
Eprazinone	mg/kg	Antitussives&Expectorants	300
Benproperine	mg/kg	Antitussives&Expectorants	2400
Brompheniramine	mg/kg	Antihistaminics	1800
Carbinoxamine	mg/kg	Antihistaminics	1650
Chlorpheniramine	mg/kg	Antihistaminics	1200
Diphenhydramine	mg/kg	Antihistaminics	30
Terfenadine	mg/kg	Antihistaminics	450
Cyproheptadine	mg/kg	Antihistaminics	60
Cetirizine	mg/kg	Antihistaminics	159
Triprolidine	mg/kg	Antihistaminics	60
Ketotifen fumarate	mg/kg	Antihistaminics	60
Astemizole	mg/kg	Antihistaminics	150

Unless otherwise agreed in writing, this document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

GZAF 173408

Test Report

Report No.: GZAFF1812022031S001

Date: Jan 14 2019

Test Items	Unit	Kind	Limit of Detection
Doxylamine	mg/kg	Antihistaminics	60
Meclizine	mg/kg	Antihistaminics	60
Promethazine	mg/kg	Antihistaminics	300
Betamethasone	mg/kg	Steroids	900
Cortisone	mg/kg	Steroids	750
Dexamethasone	mg/kg	Steroids	1200
Hydrocortisone	mg/kg	Steroids	750
Methylprednisolone	mg/kg	Steroids	750
Prednisolone	mg/kg	Steroids	1200
Prednisone	mg/kg	Steroids	750
Triamcinolone	mg/kg	Steroids	900
Betamethasone 21 Acetate	mg/kg	Steroids	4500
Betamethasone Benzoate	mg/kg	Steroids	3225
Betamethasone Dipropionate	mg/kg	Steroids	1050
Betamethasone Valerate	mg/kg	Steroids	108
Dexamethasone phosphate	mg/kg	Steroids	900
Triamcinolone acetanide	mg/kg	Steroids	4800
Clobetasol Propionate	mg/kg	Steroids	2400
Fluocinonide	mg/kg	Steroids	3600
Cortisone Acetate Crystalline	mg/kg	Steroids	3600
Carisoprodol	mg/kg	Muscle Relaxants	60
Chlormezanone	mg/kg	Muscle Relaxants	60
Chlorzoxazone	mg/kg	Muscle Relaxants	1050
Orphenadrine	mg/kg	Muscle Relaxants	30
Zolazepam HCl	mg/kg	Muscle Relaxants	60
Aminophylline	mg/kg	Bronchodilators	4500
Theophylline	mg/kg	Bronchodilators	600
Clenbuterol	mg/kg	Bronchodilators	900
Diprophylline	mg/kg	Bronchodilators	900
Fenoterol	mg/kg	Bronchodilators	750
Salbutamol	mg/kg	Bronchodilators	37.5
Oxeladin	mg/kg	Bronchodilators	120
Benzocaine	mg/kg	Local Anesthetics	300
Dibucaine	mg/kg	Local Anesthetics	450
Diclofenac	mg/kg	Local Anesthetics	600
Lidocaine	mg/kg	Local Anesthetics	30

Page 11 of 21

RAND: 37374015



Unless otherwise agreed in writing, this document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

GZAF 173409

SGS-CTI Standards Technical Services Co., Ltd.
Guangzhou Branch of SGS-CTI Standards Technical Services Co., Ltd. and Food Laboratory

No.198 Kazhu Road, Scientech Park, Guangzhou Economic & Technology Development District, Guangzhou, China 510663 t 400 - 691 - 0488 f (86-20) 82075027 www.sgs.com.cn
中国·广州·经济技术开发区科学城科珠路198号 邮编: 510663 t 400 - 691 - 0488 f (86-20) 82075027 e sgs.china@sgs.com

Member of the SGS Group (SGS SA)

Test Items	Unit	Kind	Limit of Detection
Procaine	mg/kg	Local Anesthetics	300
Tetracaine	mg/kg	Local Anesthetics	600
Naloxone	mg/kg	Local Anesthetics	384
Noscapine	mg/kg	Local Anesthetics	300
Tiletamine	mg/kg	Local Anesthetics	300
Meperidine	mg/kg	Local Anesthetics	150
Prilocaine	mg/kg	Local Anesthetics	4800
Atropine	mg/kg	Gastrointestinal Drugs	30
Bisacodyl	mg/kg	Gastrointestinal Drugs	600
Butropium	mg/kg	Gastrointestinal Drugs	3000
Camylofine	mg/kg	Gastrointestinal Drugs	3000
Cimetidine	mg/kg	Gastrointestinal Drugs	1500
Dicyclomine	mg/kg	Gastrointestinal Drugs	30
Glycopyrronium	mg/kg	Gastrointestinal Drugs	900
Homatropine	mg/kg	Gastrointestinal Drugs	60
Metoclopramide	mg/kg	Gastrointestinal Drugs	750
Oxethazaine	mg/kg	Gastrointestinal Drugs	150
Oxyphenyclimine	mg/kg	Gastrointestinal Drugs	75
Phenolphthalein	mg/kg	Gastrointestinal Drugs	600
Pirenzepine	mg/kg	Gastrointestinal Drugs	1350
Propantheline	mg/kg	Gastrointestinal Drugs	3000
Ranitidine	mg/kg	Gastrointestinal Drugs	600
Scopolamine	mg/kg	Gastrointestinal Drugs	150
Bromopride	mg/kg	Gastrointestinal Drugs	60
Dimenhydrinate	mg/kg	Gastrointestinal Drugs	150
Famotidine	mg/kg	Gastrointestinal Drugs	2400
Omeprazole	mg/kg	Gastrointestinal Drugs	2400
Acetohexamide	mg/kg	Antidiabetics	750
Chlorpropamide	mg/kg	Antidiabetics	600
Glibenclamide	mg/kg	Antidiabetics	4800
Metformin	mg/kg	Antidiabetics	300
Phenformin	mg/kg	Antidiabetics	300
Pioglitazone	mg/kg	Antidiabetics	1200
Rosiglitazone	mg/kg	Antidiabetics	3000
Tolbutamide	mg/kg	Antidiabetics	150
Glipizide	mg/kg	Antidiabetics	3000



Unless otherwise agreed in writing, this document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

GZAF 173410

Test Items	Unit	Kind	Limit of Detection
Glimepiride	mg/kg	Antidiabetics	2400
Digitoxin	mg/kg	Cardiovascular Drugs	450
Dipyridamole	mg/kg	Cardiovascular Drugs	450
Nylidrin	mg/kg	Cardiovascular Drugs	4500
Papaverine	mg/kg	Cardiovascular Drugs	1560
Diltiazem	mg/kg	Cardiovascular Drugs	300
Metoprolol	mg/kg	Cardiovascular Drugs	150
Verapamil	mg/kg	Cardiovascular Drugs	60
Amlodipine	mg/kg	Cardiovascular Drugs	300
Desacetyl diltiazem	mg/kg	Cardiovascular Drugs	60
Prazosin	mg/kg	Cardiovascular Drugs	300
Tetramethylpyrazine	mg/kg	Cardiovascular Drugs	2400
Pentoxifylline	mg/kg	Cardiovascular Drugs	2400
Clonidine	mg/kg	Cardiovascular Drugs	300
Benazepril	mg/kg	Cardiovascular Drugs	450
Bisoprolol Fumarate	mg/kg	Cardiovascular Drugs	60
Carvedilol	mg/kg	Cardiovascular Drugs	2400
Dihydroergotamine	mg/kg	Cardiovascular Drugs	150
Doxazosin	mg/kg	Cardiovascular Drugs	2400
Mexiletine	mg/kg	Cardiovascular Drugs	1500
Propafenone	mg/kg	Cardiovascular Drugs	2400
Bezafibrate	mg/kg	Antilipemic Drugs	600
Clofibrate	mg/kg	Antilipemic Drugs	1500
Etofibrate	mg/kg	Antilipemic Drugs	3000
Fenofibrate	mg/kg	Antilipemic Drugs	3000
Gemfibrozil	mg/kg	Antilipemic Drugs	4500
Nicametate	mg/kg	Antilipemic Drugs	2550
Xanthinol Niacinate	mg/kg	Antilipemic Drugs	1050
Atorvastatin	mg/kg	Antilipemic Drugs	420
Fluvastatin	mg/kg	Antilipemic Drugs	1200
Atenolol	mg/kg	Antihypertensive Drugs	300
Hydralazine	mg/kg	Antihypertensive Drugs	450
Minoxidil	mg/kg	Antihypertensive Drugs	600
Nifedipine	mg/kg	Antihypertensive Drugs	600
Propranolol	mg/kg	Antihypertensive Drugs	1350
Reserpine	mg/kg	Antihypertensive Drugs	1200

Unless otherwise agreed in writing, this document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

GZAF 173411

Test Items	Unit	Kind	Limit of Detection
Timolol Maleate	mg/kg	Antihypertensive Drugs	150
Methyl DOPA-Sesquihydrate	mg/kg	Antihypertensive Drugs	1620
Indapamide	mg/kg	Antihypertensive Drugs	2400
Carbimazole	mg/kg	Thyroid hormone and antithyroid agents	600
Liothyronine	mg/kg	Thyroid hormone and antithyroid agents	3600
Methimazole	mg/kg	Thyroid hormone and antithyroid agents	300
Chlorothiazide	mg/kg	Urinary system Drugs	750
Flavoxate	mg/kg	Urinary system Drugs	900
Furosemide	mg/kg	Urinary system Drugs	600
Hydrochlorothiazide	mg/kg	Urinary system Drugs	600
Norfloxacin	mg/kg	Urinary system Drugs	300
Phenazopyridine	mg/kg	Urinary system Drugs	750
Sulfinpyrazone	mg/kg	Urinary system Drugs	750
Oxybutynin	mg/kg	Urinary system Drugs	4635
Chloramphenicol	mg/kg	Antibiotics	1200
Econazole	mg/kg	Antibiotics	60
Griseofulvin	mg/kg	Antibiotics	450
Lomefloxacin	mg/kg	Antibiotics	1500
Ketoconazole	mg/kg	Antibiotics	300
Metronidazole	mg/kg	Antibiotics	900
Nalidixic acid	mg/kg	Antibiotics	300
Nitrofurantoin	mg/kg	Antibiotics	450
Minocycline	mg/kg	Antibiotics	750
Quinine	mg/kg	Antibiotics	300
Sulfaquinolaxaline	mg/kg	Antibiotics	4740
Sulfamonomethoxine(SMM)	mg/kg	Antibiotics	4650
Sulfadiazine	mg/kg	Antibiotics	600
Sulfadimethoxine	mg/kg	Antibiotics	750
Sulfamerazine	mg/kg	Antibiotics	450
Sulfamethazine	mg/kg	Antibiotics	600
Sulfamethizole	mg/kg	Antibiotics	600
Sulfamethoxazole	mg/kg	Antibiotics	600
Sulfamethoxypyridazine	mg/kg	Antibiotics	450
Sulfanilamide	mg/kg	Antibiotics	300
Sulfathiazole	mg/kg	Antibiotics	600
Sulfisoxazole	mg/kg	Antibiotics	450



Unless otherwise agreed in writing, this document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

GZAF 173412

Test Items	Unit	Kind	Limit of Detection
Terbinafine	mg/kg	Antibiotics	300
Tinidazole	mg/kg	Antibiotics	900
Tetracycline	mg/kg	Antibiotics	750
Trimethoprim	mg/kg	Antibiotics	300
Benzathine-penicillin	mg/kg	Antibiotics	3300
Clindamycin phosphate	mg/kg	Antibiotics	150
Cloxacillin Sodium	mg/kg	Antibiotics	4770
Chlortetracycline	mg/kg	Antibiotics	600
Ciprofloxacin(CFA)	mg/kg	Antibiotics	240
Dimetridazole	mg/kg	Antibiotics	150
Enrofloxacin	mg/kg	Antibiotics	3090
Lincomycin	mg/kg	Antibiotics	1710
Difloxacin	mg/kg	Antibiotics	3000
Ofloxacin	mg/kg	Antibiotics	1920
Oxytetracycline (OTC)	mg/kg	Antibiotics	960
Sulfisomidine	mg/kg	Antibiotics	3000
Santonin	mg/kg	Antibiotics	450
Ampicillin	mg/kg	Antibiotics	2700
Amoxicillin	mg/kg	Antibiotics	4320
Clindamycin HCl	mg/kg	Antibiotics	456
Cephalexin	mg/kg	Antibiotics	75
Cephadrine	mg/kg	Antibiotics	81
Cefazolin	mg/kg	Antibiotics	1050
Ceftriaxone	mg/kg	Antibiotics	4224
Doxycycline	mg/kg	Antibiotics	576
Erythromycin	mg/kg	Antibiotics	240
Rifampin	mg/kg	Antibiotics	120
Cefotaxime	mg/kg	Antibiotics	150
Nifuroxazide	mg/kg	Antibiotics	540
Nitrofurazone	mg/kg	Antibiotics	4410
Cefoperazone dihydrate	mg/kg	Antibiotics	300
Sulfapyridine	mg/kg	Antibiotics	2400
Cefamandole nafate	mg/kg	Antibiotics	150
Amitriptyline	mg/kg	CNS Depressants	750
Barbital	mg/kg	CNS Depressants	750
Benzhexol	mg/kg	CNS Depressants	1800



Unless otherwise agreed in writing, this document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

GZAF 173413

Test Items	Unit	Kind	Limit of Detection
Bromvalerylurea	mg/kg	CNS Depressants	1950
Chlordiazepoxide	mg/kg	CNS Depressants	300
Chlorpromazine	mg/kg	CNS Depressants	300
Cinnarizine	mg/kg	CNS Depressants	600
Cocaine	mg/kg	CNS Depressants	750
Diazepam	mg/kg	CNS Depressants	300
Diphenylhydantoin	mg/kg	CNS Depressants	150
Fluoxetine	mg/kg	CNS Depressants	1200
Lorazepam	mg/kg	CNS Depressants	300
Melatonin	mg/kg	CNS Depressants	1200
Mephensin	mg/kg	CNS Depressants	150
Meprobamate	mg/kg	CNS Depressants	150
Phenobarbital	mg/kg	CNS Depressants	900
Quetiapine	mg/kg	CNS Depressants	2400
Primidone	mg/kg	CNS Depressants	30
Secobarbital	mg/kg	CNS Depressants	900
Thioridazine	mg/kg	CNS Depressants	300
Zolpidem	mg/kg	CNS Depressants	300
Haloperidol	mg/kg	CNS Depressants	1620
Sulpiride	mg/kg	CNS Depressants	1140
Nitrazepam	mg/kg	CNS Depressants	600
Carbamazepine	mg/kg	CNS Depressants	3600
Pentobarbital	mg/kg	CNS Depressants	150
Triazolam	mg/kg	CNS Depressants	150
Imipramine	mg/kg	CNS Depressants	60
Estazolam	mg/kg	CNS Depressants	60
Clonazepam	mg/kg	CNS Depressants	150
Midazolam	mg/kg	CNS Depressants	60
Buspirone	mg/kg	CNS Depressants	3600
Maprotiline	mg/kg	CNS Depressants	150
Trazodone hydrochloride	mg/kg	CNS Depressants	3000
Norfludiazepam	mg/kg	CNS Depressants	150
Clozapine	mg/kg	CNS Depressants	3000
Clotrimazole	mg/kg	CNS Depressants	3000
Amphetamine	mg/kg	CNS Depressants	60
Caffeine	mg/kg	CNS Stimulants	600



Unless otherwise agreed in writing, this document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

GZAF 173414

Test Items	Unit	Kind	Limit of Detection
Methamphetamine	mg/kg	CNS Stimulants	60
Morphine	mg/kg	CNS Stimulants	150
Pentazocine	mg/kg	CNS Stimulants	30
Phenylephrine	mg/kg	CNS Stimulants	2850
Strychnine	mg/kg	CNS Stimulants	900
Theobromine	mg/kg	CNS Stimulants	600
Naphazoline Hydrochloride	mg/kg	CNS Depressants	300
2-Diphenylmethylpyrrolidine	mg/kg	CNS Depressants	150
Diethylstilbesterol	mg/kg	Hormone Drugs	600
Estradiol	mg/kg	Hormone Drugs	300
Estriol	mg/kg	Hormone Drugs	60
Estrone	mg/kg	Hormone Drugs	30
Ethinylestradiol	mg/kg	Hormone Drugs	30
Ethisterone	mg/kg	Hormone Drugs	600
Ethylestrenol	mg/kg	Hormone Drugs	30
Fluoxymesterone	mg/kg	Hormone Drugs	600
Methandriol	mg/kg	Hormone Drugs	2400
Methandrostenolone	mg/kg	Hormone Drugs	600
Methyltestosterone	mg/kg	Hormone Drugs	600
Nandrolone	mg/kg	Hormone Drugs	750
Norethisterone	mg/kg	Hormone Drugs	600
Oxymetholone	mg/kg	Hormone Drugs	1050
Progesterone	mg/kg	Hormone Drugs	600
Stanozolol	mg/kg	Hormone Drugs	2100
Testosterone	mg/kg	Hormone Drugs	600
Testosterone propionate	mg/kg	Hormone Drugs	3000
Norgestrel	mg/kg	Hormone Drugs	3000
Estradiol Benzoate	mg/kg	Hormone Drugs	600
Clobenzorex	mg/kg	Other	30
Diethylpropion	mg/kg	Other	450
Finasteride	mg/kg	Other	3000
Mazindol	mg/kg	Other	1950
Methaqualone	mg/kg	Other	900
Metharbital	mg/kg	Other	750
Phentermine	mg/kg	Other	60
Phentolamine	mg/kg	Other	1500



Unless otherwise agreed in writing, this document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

GZAF 173415

Test Items	Unit	Kind	Limit of Detection
Phenylpropanolamine	mg/kg	Other	60
Salicylic acid	mg/kg	Other	900
Yohimbine	mg/kg	Other	1500
Nicotine	mg/kg	Other	60
Acrinol	mg/kg	Other	2832
Apomorphine	mg/kg	Other	600
Fluconazole	mg/kg	Other	480
Isoniazid	mg/kg	Other	302.4
Naltrexone	mg/kg	Other	2370
Simvastatin	mg/kg	Other	600
Chlorhexidine	mg/kg	Other	2400
Meloxicam	mg/kg	Other	4500
Usnic acid	mg/kg	Other	3600
Baclofen	mg/kg	Other	300
Dyclonine Hydrochloride	mg/kg	Other	3600
Nefopam	mg/kg	Other	3600
Flibanserin	mg/kg	Other	3600

J: DIOXIN & PCBs^③

ITEM	METHOD	Concentration (ng/kg)	WHO-TEF (2005)	WHO-TEQ (ng/kg) Lower-bound	WHO-TEQ (ng/kg) Medium-bound	WHO-TEQ (ng/kg) Upper-bound	WHO-TEQ (ng/kg) Limit of Reporting
PCDDs & PCDFs							
2,3,7,8-TCDF	(EU) No 2017/644	< 0.0506	0.1	0.00	0.00253	0.00506	0.00506
1,2,3,7,8-PeCDF		< 0.0303	0.03	0.00	0.000454	0.000908	0.000908
2,3,4,7,8-PeCDF		< 0.0305	0.3	0.00	0.00457	0.00914	0.00914
1,2,3,4,7,8-HxCDF		< 0.0289	0.1	0.00	0.00145	0.00289	0.00289
1,2,3,6,7,8-HxCDF		< 0.0271	0.1	0.00	0.00136	0.00271	0.00271
2,3,4,6,7,8-HxCDF		< 0.0291	0.1	0.00	0.00146	0.00291	0.00291
1,2,3,7,8,9-HxCDF		< 0.0348	0.1	0.00	0.00174	0.00348	0.00348
1,2,3,4,6,7,8-HpCDF		< 0.0354	0.01	0.00	0.000177	0.000354	0.000354
1,2,3,4,7,8,9-HpCDF		< 0.0396	0.01	0.00	0.000198	0.000396	0.000396
OCDF		< 0.0287	0.0003	0.00	0.000004	0.000008	0.000008
2,3,7,8-TCDD		< 0.228	1	0.00	0.114	0.228	0.228

Page 18 of 21

RAND: 37374015

Unless otherwise agreed in writing, this document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

GZAF 173416

ITEM	METHOD	Concentration (ng/kg)	WHO-TEF (2005)	WHO-TEQ (ng/kg) Lower-bound	WHO-TEQ (ng/kg) Medium-bound	WHO-TEQ (ng/kg) Upper-bound	WHO-TEQ (ng/kg) Limit of Reporting
1,2,3,7,8-PeCDD		< 0.106	1	0.00	0.0528	0.106	0.106
1,2,3,4,7,8-HxCDD		< 0.0543	0.1	0.00	0.00271	0.00543	0.00543
1,2,3,6,7,8-HxCDD		< 0.0514	0.1	0.00	0.00257	0.00514	0.00514
1,2,3,7,8,9-HxCDD		< 0.0539	0.1	0.00	0.00270	0.00539	0.00539
1,2,3,4,6,7,8-HpCDD		< 0.0359	0.01	0.00	0.000180	0.000359	0.000359
OCDD		< 0.0311	0.0003	0.00	0.000004 66	0.000009 32	0.000009 32
Total (PCDDs & PCDFs)				0.00	0.189	0.378	0.378
Non-ortho PCBs							
3,4,4',5-PCB (81)		< 0.470	0.0003	0.00	0.000070 5	0.000141	0.000141
3,3',4,4'-PCB (77)		0.773	0.0001	0.0000 773	0.000077 3	0.000077 3	0.000054 8
3,3',4,4',5-PCB (126)	(EU) No 2017/644	< 0.422	0.1	0.00	0.0211	0.0422	0.0422
3,3',4,4',5,5'-PCB (169)		< 0.229	0.03	0.00	0.00344	0.00688	0.00688
Mono-ortho PCBs							
2',3,4,4',5-PCB (123)		< 0.319	0.0000 3	0.00	0.000004 78	0.000009 57	0.000009 57
2,3',4,4',5-PCB (118)		3.30	0.0000 3	0.0000 989	0.000098 9	0.000098 9	0.000009 33
2,3,4,4',5-PCB (114)		< 0.377	0.0000 3	0.00	0.000005 66	0.000011 3	0.000011 3
2,3,3',4,4'-PCB (105)	(EU) No 2017/644	< 0.318	0.0000 3	0.00	0.000004 78	0.000009 55	0.000009 55
2,3',4,4',5,5'-PCB (167)		< 0.606	0.0000 3	0.00	0.000009 09	0.000018 2	0.000018 2
2,3,3',4,4',5-PCB (156)		< 0.353	0.0000 3	0.00	0.000005 29	0.000010 6	0.000010 6
2,3,3',4,4',5'-PCB (157)		< 0.285	0.0000 3	0.00	0.000004 27	0.000008 54	0.000008 54
2,3,3',4,4',5,5'-PCB (189)		< 0.446	0.0000 3	0.00	0.000006 69	0.000013 4	0.000013 4
Total (DL-PCBs)				0.0001 76	0.0248	0.0495	0.0494
Total (PCDF/D+DLPCB)				0.0001 76	0.214	0.427	



Unless otherwise agreed in writing, this document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

GZAF 173417

WHO-TEF: Toxic Equivalency Factor

Lowerbound concentration: For the calculation of the total concentration, the values, which were lower than the limit of reporting, were regarded as zero.

Mediumbound concentration: For the calculation of the total mediumbound concentration, the values, which were lower than the limit of reporting, were regarded as the half of the limit of reporting.

Upperbound concentration: For the calculation of the total upperbound concentration, the values, which were lower than the limit of reporting, were regarded as the value of the limit of reporting.

ITEM	METHOD	Extraction Standards Rec (%)
Extraction Standards Rec (%)		
¹³ C-2,3,7,8-TCDF	(EU) No 2017/644	48 (**)
¹³ C-1,2,3,7,8-PeCDF		66
¹³ C-2,3,4,7,8-PeCDF		62
¹³ C-1,2,3,4,7,8-HxCDF		66
¹³ C-1,2,3,6,7,8-HxCDF		68
¹³ C-2,3,4,6,7,8-HxCDF		65
¹³ C-1,2,3,7,8,9-HxCDF		68
¹³ C-1,2,3,4,6,7,8-HpCDF		69
¹³ C-1,2,3,4,7,8,9-HpCDF		67
¹³ C-2,3,7,8-TCDD		90
¹³ C-1,2,3,7,8-PeCDD		68
¹³ C-1,2,3,4,7,8-HxCDD		67
¹³ C-1,2,3,6,7,8-HxCDD		77
¹³ C-1,2,3,4,6,7,8-HpCDD		75
¹³ C-OCDD		66
Purify Standard Rec (%)		
37Cl4-2,3,7,8-TCDD	(EU) No 2017/644	77
Extraction Standards Rec (%)		
Non-ortho PCBs		
3,4,4',5-PCB (81)	(EU) No 2017/644	66
3,3',4,4'-PCB (77)		66
3,3',4,4',5-PCB (126)		81
Mono-ortho PCBs		
2',3,4,4',5-PCB (123)	(EU) No 2017/644	72
2,3',4,4',5-PCB (118)		75



Unless otherwise agreed in writing, this document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

GZAF 173418

ITEM	METHOD	Extraction Standards Rec (%)
2,3,4,4',5-PCB (114)		60
2,3,3',4,4'-PCB (105)		78
2,3',4,4',5,5'-PCB (167)		63
2,3,3',4,4',5-PCB (156)		58 (**)
2,3,3',4,4',5'-PCB (157)		62
2,3,3',4,4',5,5'-PCB (189)		56 (**)

(**) Recoveries do not meet the quality criteria of the analytical method.

Remark:

1. ND=Not Detected.
2. ①Test the content.
3. *The test result is only for reference.
4. ②The contents of the fatty acids were determined by using the normalization method.
5. ③The test(s) was(were) carried out by a SGS laboratory.
6. NR: No Recovery.

*** End of Report***



Unless otherwise agreed in writing, this document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

GZAF 173419